Doxazosin Mesylate, Extended Release — Competitive Intelligence Brief

Doxazosin Mesylate, Extended Release (Doxazosin Mesylate, Extended Release) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-1 adrenergic receptor antagonist. Area: Urology.

phase 2 Alpha-1 adrenergic receptor antagonist Alpha-1 adrenergic receptor Urology Small molecule

Target snapshot

Doxazosin Mesylate, Extended Release (Doxazosin Mesylate, Extended Release) — San Francisco Veterans Affairs Medical Center. Doxazosin mesylate is an alpha-1 adrenergic receptor antagonist that relaxes smooth muscle in the prostate and bladder neck, improving urine flow and reducing symptoms of benign prostatic hyperplasia.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Doxazosin Mesylate, Extended Release TARGET	Doxazosin Mesylate, Extended Release	San Francisco Veterans Affairs Medical Center	phase 2	Alpha-1 adrenergic receptor antagonist	Alpha-1 adrenergic receptor
Placebo to Prazosin	Placebo to Prazosin	Brian J Lipworth	marketed	Alpha-1 adrenergic receptor antagonist	Alpha-1 adrenergic receptor
placebo; diphenhydramine/phenylephrine/cocoa; dextromethorphan	placebo; diphenhydramine/phenylephrine/cocoa; dextromethorphan	Montefiore Medical Center	marketed	Combination cold and cough remedy	H1 receptor (diphenhydramine); alpha-1 adrenergic receptor (phenylephrine); sigma-1 receptor and NMDA receptor (dextromethorphan)
eye drops (Phenylephrin)	eye drops (Phenylephrin)	Medical University of Graz	marketed	Alpha-1 adrenergic agonist	Alpha-1 adrenergic receptor
Midodrine + pyridostigmine	Midodrine + pyridostigmine	Seoul National University Hospital	marketed	Alpha-1 adrenergic agonist + acetylcholinesterase inhibitor combination	Alpha-1 adrenergic receptor; acetylcholinesterase
Bupivacaine-adrenaline	Bupivacaine-adrenaline	University of Aarhus	marketed	Local anesthetic with vasopressor	Voltage-gated sodium channels; alpha-1 adrenergic receptors (adrenaline component)
RASi plus carvedilol	RASi plus carvedilol	Federal University of Minas Gerais	marketed	ACE inhibitor or ARB combined with non-selective beta-blocker	Angiotensin II receptor / ACE enzyme; beta-1 and beta-2 adrenergic receptors; alpha-1 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-1 adrenergic receptor antagonist class)

1. Brian J Lipworth · 1 drug in this class
2. CHU de Quebec-Universite Laval · 1 drug in this class
3. Eli Lilly and Company · 1 drug in this class
4. Haffkine Bio-Pharmaceutical Corporation Ltd. · 1 drug in this class
5. Hospital Authority, Hong Kong · 1 drug in this class
6. Japan Heart Foundation · 1 drug in this class
7. Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · 1 drug in this class
8. San Francisco Veterans Affairs Medical Center · 1 drug in this class
9. Sanofi · 1 drug in this class
10. Shanghai Huilun Pharmaceutical Co., Ltd. · 1 drug in this class